However, the treatment of brain metastases secondary to breast cancer can be challenging despite the use of Trastuzumab (TZ), an anti-HER2 antibody that has been shown to ameliorate patients’ survival; in fact, TZ has poor penetrance to the CNS [101,102,103]. This evidence concerns the gene ERBB2 and breast carcinoma.